Given the clinical picture including COVID-19, depressed C3 complement level, acute kidney injury, normal ADAMTS13 level, and response to eculizumab, aHUS triggered by COVID-19 was the most likely diagnosis. This evidence concerns the gene ADAMTS13 and acute kidney injury.